Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Batycky

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Aerosol Medicine and Pulmonary Drug Delivery|November 22, 2017
Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's DiseasePeter A LeWitt, Rajesh Pahwa, Alexander Sedkov, et al.
Science Translational Medicine|October 14, 2016
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's diseaseMichael M Lipp, Richard Batycky, Jerome Moore, et al.
The Lancet. Neurology|January 22, 2019
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialPeter A LeWitt, Robert A Hauser, Rajesh Pahwa, et al.
QRB Discovery|June 30, 2021
A New Natural Defense Against Airborne PathogensDavid Edwards, Anthony Hickey, Richard Batycky, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Aerosol Medicine and Pulmonary Drug Delivery|November 22, 2017
Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's DiseasePeter A LeWitt, Rajesh Pahwa, Alexander Sedkov, et al.
Science Translational Medicine|October 14, 2016
Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's diseaseMichael M Lipp, Richard Batycky, Jerome Moore, et al.
The Lancet. Neurology|January 22, 2019
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialPeter A LeWitt, Robert A Hauser, Rajesh Pahwa, et al.
QRB Discovery|June 30, 2021
A New Natural Defense Against Airborne PathogensDavid Edwards, Anthony Hickey, Richard Batycky, et al.
Pageof 1